THRIVE I: Efficacy and tolerability of the novel, oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis.
Conferences
- Overview
- Research
- Additional Document Info
- View All
Overview
status
publication date
- November 16, 2001
has subject area
- 1102 Cardiorespiratory Medicine and Haematology (FoR)
- 1103 Clinical Sciences (FoR)
- 1114 Paediatrics and Reproductive Medicine (FoR)
- Immunology (Science Metrix)
published in
- Blood Journal